(MedPage Today) — The FDA on Friday granted accelerated approval to elamipretide (Forzinity) as the first treatment for the ultra-rare Barth syndrome, which affects approximately 150 Americans.
Elamipretide once-daily injections are now indicated…
Source link : https://www.medpagetoday.com/publichealthpolicy/fdageneral/117592
Author :
Publish date : 2025-09-22 21:39:00
Copyright for syndicated content belongs to the linked Source.
